Tech Company Financing Transactions
Peloton Therapeutics Funding Round
Peloton Therapeutics closed a $150 million Series E funding round on 2/21/2019. Backers included RA Capital, BVF Partners and Curative Ventures.
Transaction Overview
Company Name
Announced On
2/21/2019
Transaction Type
Venture Equity
Amount
$150,000,000
Round
Series E
Investors
Proceeds Purpose
Proceeds from this financing will be used to advance Peloton's research and development pipeline, including our lead drug candidate, PT2977, a potent and selective oral HIF-2a inhibitor.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2330 Inwood Rd. 226
Dallas, TX 75235
USA
Dallas, TX 75235
USA
Phone
Website
Email Address
Overview
Working in close collaboration with scientists at UT Southwestern, Peloton is advancing a promising discovery and development pipeline, comprised of several small molecule-based programs, each with a distinct target and mechanism of action.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Josey
Chief Financial Officer
Alan Musso
Chief Medical Officer
Mohammad Hirmand
Chief Scientific Officer
Eli Wallace
Vice President
James Rizzi
Vice President
Naseem Zojwalla
VP - General Counsel
John Moore
VP - Operations
Michael Bakes
VP - Regulatory Affairs
Cheryl Madsen
Browse more venture capital transactions:
Prev: 2/21/2019: Clutter venture capital transaction
Next: 2/21/2019: ThousandEyes venture capital transaction
Share this article
News on VC Transactions
We document all VC transactions involving tech companies. VC investment data records on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs